The Australian stock market recently experienced a broad downturn, with the ASX200 closing down 1.7% at 7,843 points and all sectors losing ground, particularly materials and energy. In such volatile conditions, investors often seek out growth companies with high insider ownership as these firms can offer a sense of stability and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Australia

Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Emerald Resources

Simply Wall St Growth Rating: ★★★★★★

Overview: Emerald Resources NL is involved in the exploration and development of mineral reserves in Cambodia and Australia, with a market cap of A$2.43 billion.

Operations: The company's revenue primarily comes from its mine operations, amounting to A$427.32 million.

Insider Ownership: 18.1%

Emerald Resources has demonstrated strong growth potential with earnings increasing by 32.2% over the past year, and revenue forecasted to grow at 28.6% annually, outpacing the Australian market. Recent results show sales of A$239.73 million for H1 2024, up from A$176.75 million a year ago, alongside record gold production at Okvau Gold Mine. Insider activity remains positive with substantial buying in recent months and no significant selling reported, reflecting confidence in future performance.

• Get an in-depth perspective on Emerald Resources' performance by reading our analyst estimates report here.
• The analysis detailed in our Emerald Resources valuation report hints at an deflated share price compared to its estimated value.

Guzman y Gomez

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Guzman y Gomez Limited owns, operates, and franchises quick service restaurants in Australia, Singapore, Japan, and the United States with a market cap of A$3.27 billion.

Operations: The company generates revenue primarily through its quick service restaurant operations, with A$413.26 million attributed to this segment.

Insider Ownership: 13.5%

Guzman y Gomez shows promising growth potential, with half-year sales rising to A$212.42 million from A$167.29 million and a net income of A$7.3 million compared to a previous loss. Revenue is expected to grow at 18.7% annually, surpassing the Australian market average of 5.8%. The company is forecasted to achieve profitability within three years, although return on equity remains modest at an estimated 15%. No significant insider trading activity has been reported recently.

• Click here to discover the nuances of Guzman y Gomez with our detailed analytical future growth report.
• In light of our recent valuation report, it seems possible that Guzman y Gomez is trading beyond its estimated value.

PYC Therapeutics

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market cap of A$672.15 million.

Operations: The company generates revenue primarily from its activities in the discovery and development of novel RNA therapeutics, amounting to A$24.99 million.

Insider Ownership: 38%

PYC Therapeutics demonstrates growth potential with a recent half-year revenue increase to A$12.69 million from A$9.12 million, despite a widening net loss of A$25.57 million. The company completed a follow-on equity offering raising approximately A$145.82 million, indicating shareholder confidence but also resulting in substantial dilution over the past year. Revenue is forecasted to grow at 14.2% annually, outpacing the Australian market average, and profitability is expected within three years despite low projected return on equity at 7.3%.

• Dive into the specifics of PYC Therapeutics here with our thorough growth forecast report.
• Upon reviewing our latest valuation report, PYC Therapeutics' share price might be too optimistic.

Make It Happen

• Dive into all 94 of the Fast Growing ASX Companies With High Insider Ownership we have identified here.
• Ready For A Different Approach? AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:EMR ASX:GYG and ASX:PYC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com